Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib.

Martina Tilio,Valentina Gambini,Junbiao Wang,Chiara Garulli,Cristina Kalogris,Cristina Andreani,Caterina Bartolacci,Maria Elexpuru Zabaleta,Lucia Pietrella,Albana Hysi,Manuela Iezzi,Barbara Belletti,Fiorenza Orlando,Mauro Provinciali,Roberta Galeazzi,Cristina Marchini,Augusto Amici

Cancer Letters（2016）

引用 21|浏览35

暂无评分

摘要

•Saracatinib and Dacomitinib block the oncogenic Δ16HER2/Src axis in vitro.•Erk signaling escape pathway mediates acquired resistance to Saracatinib in vivo.•Δ16HER2+ breast tumors are refractory to reversible TKI Lapatinib.•Δ16HER2+ breast tumors are responsive to irreversible TKI Dacomitinib.

查看译文

关键词

HER2 isoform,Breast cancer,Δ16HER2 mice,Targeted therapies,Drug resistances

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要